184 related articles for article (PubMed ID: 18473856)
1. Design, synthesis and development of novel camptothecin drugs.
Liew ST; Yang LX
Curr Pharm Des; 2008; 14(11):1078-97. PubMed ID: 18473856
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
3. Novel camptothecin derivatives.
Legarza K; Yang LX
In Vivo; 2005; 19(1):283-92. PubMed ID: 15796188
[TBL] [Abstract][Full Text] [Related]
4. A review of the clinical experience with irinotecan (CPT-11).
Horowitz RW; Wadler S; Wiernik PH
Am J Ther; 1997; 4(5-6):203-10. PubMed ID: 10423612
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies of camptothecin and derivatives.
Soepenberg O; Sparreboom A; Verweij J
Alkaloids Chem Biol; 2003; 60():1-50. PubMed ID: 14593855
[No Abstract] [Full Text] [Related]
6. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Mross K; Steinbild S; Baas F; Reil M; Buss P; Mersmann S; Voliotis D; Schwartz B; Brendel E
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):618-9. PubMed ID: 14692719
[No Abstract] [Full Text] [Related]
7. Review camptothecin: current perspectives.
Li QY; Zu YG; Shi RZ; Yao LP
Curr Med Chem; 2006; 13(17):2021-39. PubMed ID: 16842195
[TBL] [Abstract][Full Text] [Related]
8. [CPT-11: new drug for metastatic colorectal cancer].
Barone C; Pozzo C; Cassano A
Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
[No Abstract] [Full Text] [Related]
9. Clinical pharmacology and pharmacodynamics of irinotecan. A review.
Chabot GG
Ann N Y Acad Sci; 1996 Dec; 803():164-72. PubMed ID: 8993509
[No Abstract] [Full Text] [Related]
10. Clinical pharmacology of camptothecins.
Iyer L; Ratain MJ
Cancer Chemother Pharmacol; 1998; 42 Suppl():S31-43. PubMed ID: 9750027
[TBL] [Abstract][Full Text] [Related]
11. Recent clinical advances with camptothecin analogues.
Slichenmyer WJ; Donehower RC
Cancer Treat Res; 1995; 78():29-43. PubMed ID: 8595145
[No Abstract] [Full Text] [Related]
12. Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Ann N Y Acad Sci; 1996 Dec; 803():173-80. PubMed ID: 8993510
[No Abstract] [Full Text] [Related]
13. Topoisomerase I inhibitors: topotecan and irenotecan.
Creemers GJ; Lund B; Verweij J
Cancer Treat Rev; 1994 Jan; 20(1):73-96. PubMed ID: 8293429
[No Abstract] [Full Text] [Related]
14. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.
Yurkovetskiy AV; Fram RJ
Adv Drug Deliv Rev; 2009 Nov; 61(13):1193-202. PubMed ID: 19682517
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
Herben VM; Ten Bokkel Huinink WW; Schellens JH; Beijnen JH
Pharm World Sci; 1998 Aug; 20(4):161-72. PubMed ID: 9762728
[TBL] [Abstract][Full Text] [Related]
16. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
17. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Garcia-Carbonero R; Supko JG
Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
[TBL] [Abstract][Full Text] [Related]
18. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Lavergne O; Bigg DC
Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
[TBL] [Abstract][Full Text] [Related]
19. Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives.
Rivory LP; Robert J
Pharmacol Ther; 1995; 68(2):269-96. PubMed ID: 8719971
[TBL] [Abstract][Full Text] [Related]
20. An overview on the development of new potentially active camptothecin analogs against cancer.
Chazin Ede L; Reis Rda R; Junior WT; Moor LF; Vasconcelos TR
Mini Rev Med Chem; 2014; 14(12):953-62. PubMed ID: 25355593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
